We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quercus Ilex and Quercus Robur Allergen Extracts Standardisation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05532566
Recruitment Status : Not yet recruiting
First Posted : September 8, 2022
Last Update Posted : September 8, 2022
Sponsor:
Information provided by (Responsible Party):
Inmunotek S.L.

Brief Summary:
The objective of this study is to determine the biological activity of Quercus illex and Quercus robur allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).

Condition or disease Intervention/treatment Phase
Allergic Reaction Allergic Skin Reaction Allergy Pollen Other: Allergenic extract Not Applicable

Detailed Description:

The trial will consist of a single visit, in which the following procedures will be carried out:

  • Demographic data.
  • Clinical history.
  • Inclusion/exclusion criteria.
  • General examination.
  • Performance of prick-tests (3 concentrations of Quercus ilex allergenic extract, 3 concentrations of Quercus robur allergenic extract, positive control and negative control).
  • Obtaining a blood sample from the patient to create a pool of sera for the "in vitro" standardization of the allergenic extract. This pool of sera is necessary for the characterization of the Company's standard. Each serum sample will be stored in a tube that will be labeled with the subject number and frozen. These serum samples will remain in the freezer until the study is completed. When the study is completed, they will be transported to the laboratory, where all sera will be pooled. This "pool" of sera will be used to perform the complementary in vitro standardization tests. These include ELISA for measurement of inhibition against specific IgE, etc. These serum samples are not destroyed. They are pooled together to form a pool that will be used, as described in the previous paragraph, in all the in vitro tests necessary to standardize and characterize this extract and produce its corresponding HIRP (In-house reference preparation), as indicated by the Royal Spanish Pharmacopoeia and the European Pharmacopoeia. This pool of sera is not destroyed, it is used in the in vitro analyses necessary for the standardization of new batches of this allergenic extract. Once the pool has been formed, the tubes containing the original serum samples are destroyed.
  • Evaluation of adverse events.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Phase II, open-label, non-randomized trial, with no control group of subjects.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Quercus Ilex and Quercus Robur Allergen Extracts. Determination of the in Vivo Allergenic Potency in Histamine Equivalent Units (HEP).
Estimated Study Start Date : January 2, 2023
Estimated Primary Completion Date : January 31, 2024
Estimated Study Completion Date : April 30, 2024

Arm Intervention/treatment
Experimental: Extract Q. ilex + extract Q. robur + positive control + negative control

There is only one treatment arm. In each subject, one drop of each of the 3 concentrations of each allergenic extract (2 extracts) will be applied in addition to the positive control (histamine 10mg/mL) and the negative control, with prick test.

Quercus ilex: 2,500, 500 and 100 μg/mL Quercus robur: 2,500, 500 and 100 μg/mL

Other: Allergenic extract
In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
Other Name: Allergenic Quercus ilex and Quercus robur extract




Primary Outcome Measures :
  1. Size of the induced papule on the skin [ Time Frame: 15 minutes ]
    Size of the induced papule on the skin when applying each of the concentrations of the allergenic extracts and the positive (histamine) and negative controls, using the prick test.

  2. Adverse reactions [ Time Frame: 30 minutes ]
    Mild secondary reactions such as pruritus, erythema, local edema, etc. There is a risk, infrequent and exceptional, of systemic reactions, sometimes severe (urticaria, asthma, anaphylactic shock, etc.).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must live in a geographical area where allergic problems caused by Quercus ilex and Quercus robur are relevant.
  • Positive clinical history of inhalant allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) to asthma) to Quercus ilex and Quercus robur.
  • A positive prick-test (mean papule diameter ≥ 3 mm) with an extract of the same allergen and/or presence of specific IgE against that allergen.
  • The mean papule area obtained with Histamine dichlorhydrate at 10 mg/mL should be ≥ 7 mm2.
  • Age: Between 18 and 64 years old.
  • Subjects must be able to give informed consent.

Exclusion Criteria:

  • Subjects should not be excluded in terms of low or high sensitivity to Quercus ilex and Quercus robur.
  • Subjects outside the age range.
  • Subjects who have previously received immunotherapy in the last 5 years for the treatment of asthma or rhinoconjunctivitis for the treatment of asthma or allergic rhinoconjunctivitis induced by allergens that may interfere with Quercus ilex and Quercus robur extracts.
  • Subjects with significant symptoms of rhinoconjunctivitis and/or bronchial asthma in which the suspension of the systemic antihistamine treatment is contraindicated.
  • Subjects who have previously presented a severe secondary reaction during the performance of diagnostic skin tests by prick test.
  • Subjects under treatment with ß-blockers.
  • Subjects clinically unstable (acute asthma, febrile, etc.).
  • Subjects with active urticaria lesions, severe active dermographism, severe atopic dermatitis, sunburn, eczema, psoriasis lesions in the area where the prick test is performed (risk of false positives).
  • Subjects with active viral infection by herpes simplex or herpes varicella zoster in the area where the prick test is performed.
  • Subjects with any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, HTA, cardiopathy, etc.).
  • States of the subject in which he/she cannot offer cooperation and severe psychiatric disorders.
  • Pregnant women or women at risk of pregnancy and lactating women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05532566


Contacts
Layout table for location contacts
Contact: Miguel Casanovas 912908942 ext 34 mcasanovas@inmunotek.com
Contact: Raquel Caballero 607600638 ext 34 rcaballero@inmunotek.com

Locations
Layout table for location information
Spain
Clínica Subiza, centro de asma y alergia
Madrid, Spain
Principal Investigator: Javier Subiza, DM         
Sponsors and Collaborators
Inmunotek S.L.
Investigators
Layout table for investigator information
Principal Investigator: Javier Subiza, DM Clinica Subiza, centro de asma y alergia
Publications:
Layout table for additonal information
Responsible Party: Inmunotek S.L.
ClinicalTrials.gov Identifier: NCT05532566    
Other Study ID Numbers: T525-STD-043
2020-005388-30 ( EudraCT Number )
First Posted: September 8, 2022    Key Record Dates
Last Update Posted: September 8, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Inmunotek S.L.:
Allergy
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis, Allergic, Seasonal
Hypersensitivity
Immune System Diseases
Rhinitis, Allergic
Rhinitis
Nose Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Otorhinolaryngologic Diseases
Hypersensitivity, Immediate